Multimodal imaging in the characterization of tumors to assess tumor aggressiveness, diagnostic work-up and treatment response evaluation in prostate cancer, cervical cancer, breast cancer, sarcomas, spinal metastases, neuroendocrine tumors, GISTs, colorectal cancers, liver malignancies, multiple myeloma and lymphoma
Characterization of vascular inflammation inclusive vulnerability in atherosclerosis, treatment selection and treatment response evaluation using PET, MRI and US
Detection and treatment response evaluation in inflammatory and fibrosing diseases using different imaging modalities and PET tracers
Characterize pituritary microadenomas, remnant adenomas following surgery and hypophysitis by the use of different MRI and PET techniques
Radionuclide therapies for treatment of non-Hodgkin lymphoma, neuroendocrine tumors (NET) and Selective Internal Radiation Therapy (SIRT)
Development and testing of novel radionuclide therapies with emphasis on alpha-emitters
Molecular imaging and quantification of neurological diseases
Ultrasound-guided percutaneous ethanol injection treatment in patients with metastatic lymph nodes from thyroid carcinoma
Development of new biomarkers using radiomics and artificial intelligence (AI) for the characterization of diseases
McDonald EO, Amanullah AA, Park PSU, Song W, Werner TJ, Alavi A, Revheim ME(2023) The role of 18F-FDG PET/CT in primary cutaneous lymphoma: an educational review Ann Nucl Med, 37(6), 328-348 DOI 10.1007/s12149-023-01830-3, PubMed 37095393
Singh SB, Bhandari S, Siwakoti S, Bhatta R, Raynor WY, Werner TJ, Alavi A, Hess S, Revheim ME(2023) Is Imaging Bacteria with PET a Realistic Option or an Illusion? Diagnostics (Basel), 13(7) DOI 10.3390/diagnostics13071231, PubMed 37046449
Griffin MT, Werner TJ, Alavi A, Revheim ME(2023) The value of FDG-PET/CT imaging in the assessment, monitoring, and management of COVID-19 Eur Phys J Plus, 138(3), 283 DOI 10.1140/epjp/s13360-023-03797-6, PubMed 37008755